A phase I dose escalation study of intravesical TMX-101 in subjects with Non-Muscle-Invasive Bladder Cancer

Trial Profile

A phase I dose escalation study of intravesical TMX-101 in subjects with Non-Muscle-Invasive Bladder Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2013

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Telormedix
  • Most Recent Events

    • 26 Aug 2013 New source identified and integrated (ISRCTN: Current Controlled Trials)
    • 21 Aug 2013 Status changed from recruiting to completed, according to ISRCTN: Current Controlled Trials
    • 10 Jan 2012 Telormedix received CHF7.5 million in financing, which in part, will be used to support this trial, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top